DAUNORUBICIN Side Effects

5968253-6 | Abdominal Abscess, Inflammation
on Nov 22, 2008 Male patient from UNITED STATES , weighting 89.73 lb, was treated with Daunorubicin (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal abscess, inflammation. Daunorubicin dosage: 132 Mg. During the same period patient was treated with METHOTREXATE (15 Mg) (View Methotrexate Review and Methotrexate Label ), PEG L ASPARAGINASE (K H) (3250 Iu) (View Peg-l-asparaginase (k-h) Review and Peg-l-asparaginase (k-h) Label ), PREDNISONE TAB (22240 Mg) (View Prednisone Tab Review and Prednisone Tab Label ), VINCRISTINE SULFATE (8 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DIPHENHYDRAMINE HCL (View Diphenhydramine Hcl Review and Diphenhydramine Hcl Label ), PROMETHAZINE (View Promethazine Review and Promethazine Label ), CYTARABINE (70 Mg) (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

5049863-X | Metastatic Neoplasm, Renal Mass
Patient was taking Daunorubicin (View Usage). Patient had the following side effects: metastatic neoplasm, renal mass on Jun 21, 2006 from UNITED STATES Additional patient health information: Male patient , 16 years of age, was diagnosed with acute promyelocytic leukaemia and. Daunorubicin dosage: 38 Milligram Intravenous (nos). During the same period patient was treated with DEXAMETHASONE TAB (380 Milligram Intravenous (nos)) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), CYTARABINE (180 Milligram Intravenous (nos)) (View Cytarabine Review and Cytarabine Label ), TIOGUANINE (180 Milligram Intravenous (nos)) (View Tioguanine Review and Tioguanine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ).

5001627-9 | Deep Vein Thrombosis, Febrile Neutropenia, Pneumonia, Pulmonary Embolism, Pulmonary Infarction
Adverse event was reported on May 11, 2006 by a Male patient taking Daunorubicin (View Usage) (Dosage: 462 Mg) was diagnosed with acute lymphocytic leukaemia and. Location: UNITED STATES , weighting 177.9 lb, After Daunorubicin was administered, patient had the following side effects: deep vein thrombosis (What is deep vein thrombosis?), febrile neutropenia, pneumonia (What is pneumonia?), pulmonary embolism (What is pulmonary embolism?), pulmonary infarction. During the same period patient was treated with ELSPAR (120000 Iu) (View Elspar Review and Elspar Label ), METHOTREXATE (12.5 Mg) (View Methotrexate Review and Methotrexate Label ), PREDNISONE TAB (3360 Mg) (View Prednisone Tab Review and Prednisone Tab Label ), VINCRISTINE SULFATE (8 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

4932976-8 | Hypotension
on Mar 01, 2006 Female patient from UNITED STATES , weighting 174.2 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Daunorubicin (View Usage). Patient experienced the following unwanted or unexpected effects: hypotension. Daunorubicin dosage: 318 Mg. During the same period patient was treated with DEXAMETHASONE (140 Mg) (View Dexamethasone Review and Dexamethasone Label ), G CSF (FILGRASTIM, AMGEN) (3360 Mg) (View G-csf (filgrastim, Amgen) Review and G-csf (filgrastim, Amgen) Label ), ELSPAR (31860 Unit) (View Elspar Review and Elspar Label ), VINCRISTINE SULFATE (4 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.


4917202-8 | Dysphagia, Mouth Haemorrhage, Mucosal Exfoliation, Mucosal Inflammation, Open Wound, Oral Intake Reduced, Tongue Disorder
on Feb 16, 2006 Female patient from UNITED STATES , weighting 123.9 lb, was diagnosed with acute myeloid leukaemia and was treated with Daunorubicin (View Usage). Patient had the following side effects: dysphagia, mouth haemorrhage, mucosal exfoliation, mucosal inflammation, open wound, oral intake reduced, tongue disorder. Daunorubicin dosage: 420 Mg. During the same period patient was treated with ETOPOSIDE (468 Mg) (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

4894867-0 | Asthenia, Blood Culture Positive, Febrile Neutropenia, Leukostasis, Sepsis, Sputum Culture Positive, Staphylococcal Infection, Transient Ischaemic Attack
Patient was taking Daunorubicin (View Usage). After Daunorubicin was administered, patient had the following side effects: asthenia, blood culture positive, febrile neutropenia, leukostasis, sepsis (What is sepsis?), sputum culture positive, staphylococcal infection (What is staphylococcal infection?), transient ischaemic attack on Jan 27, 2006 from UNITED STATES Additional patient health information: Male patient , weighting 246.9 lb, was diagnosed with acute lymphocytic leukaemia and. Daunorubicin dosage: See Image. During the same period patient was treated with DEXAMETHASONE TAB (See Image) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), ELSPAR (See Image) (View Elspar Review and Elspar Label ), VINCRISTINE SULFATE (See Image) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

4887964-7 | Asthenia, Leukostasis, Transient Ischaemic Attack
Adverse event was reported on Jan 19, 2006 by a Male patient taking Daunorubicin (View Usage) (Dosage: See Image) was diagnosed with acute lymphocytic leukaemia and. Location: UNITED STATES , weighting 246.9 lb, Patient experienced the following unwanted or unexpected effects: asthenia, leukostasis, transient ischaemic attack. During the same period patient was treated with DEXAMETHASONE TAB (See Image) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), VINCRISTINE SULFATE (See Image) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

4886272-8 | Aphasia, Autoantibody Positive, Autoimmune Disorder, Bone Marrow Failure, Haemorrhage Intracranial, Thrombocytopenia
on Jan 18, 2006 Female patient from UNITED STATES , 43 years of age, weighting 163.1 lb, was diagnosed with acute myelomonocytic leukaemia and was treated with Daunorubicin (View Usage). Patient had the following side effects: aphasia (What is aphasia?), autoantibody positive, autoimmune disorder, bone marrow failure, haemorrhage intracranial, thrombocytopenia. Daunorubicin dosage: 45 Mg/m2 Daily Times 3 Days Iv. During the same period patient was treated with CYTARABINE (100 Mg/m2 7 Days Cont. Infus Iv Drip) (View Cytarabine Review and Cytarabine Label ).

4876073-9 | Mucosal Inflammation, Pain, Pharyngitis, Stomatitis
on Jan 06, 2006 Female patient from UNITED STATES , weighting 146.6 lb, was diagnosed with acute myeloid leukaemia and was treated with Daunorubicin (View Usage). After Daunorubicin was administered, patient had the following side effects: mucosal inflammation, pain (What is pain?), pharyngitis, stomatitis. Daunorubicin dosage: See Image. During the same period patient was treated with CYTARABINE (See Image) (View Cytarabine Review and Cytarabine Label ), GM CSF (See Image) (View Gm-csf Review and Gm-csf Label ). Patient was hospitalized.

4874734-9 | Blood Culture Positive, Convulsion, Depressed Level Of Consciousness, Electroencephalogram Abnormal, Fungal Infection, Hypotension, Hypoxia, Mental Status Changes, Multi-organ Failure
Patient was taking Daunorubicin (View Usage). Patient experienced the following unwanted or unexpected effects: blood culture positive, convulsion, depressed level of consciousness, electroencephalogram abnormal, fungal infection (What is fungal infection?), hypotension, hypoxia, mental status changes, multi-organ failure on Jan 01, 2006 from UNITED STATES Additional patient health information: Male patient , weighting 198.4 lb, was diagnosed with acute lymphocytic leukaemia and. Daunorubicin dosage: See Image. During the same period patient was treated with VINCRISTINE (See Image) (View Vincristine Review and Vincristine Label ), PREDNISONE (See Image) (View Prednisone Review and Prednisone Label ), PEG ASPARIGINASE (See Image) (View Peg-aspariginase Review and Peg-aspariginase Label ). Patient was hospitalized.

4865089-4 | Abdominal Pain, Hypotension, Hypoxia, Liver Function Test Abnormal, Mental Status Changes, Pancreatitis
Adverse event was reported on Dec 20, 2005 by a Male patient taking Daunorubicin (View Usage) (Dosage: See Image) was diagnosed with acute lymphocytic leukaemia and. Location: UNITED STATES , weighting 198.4 lb, Patient had the following side effects: abdominal pain (What is abdominal pain?), hypotension, hypoxia, liver function test abnormal, mental status changes, pancreatitis. During the same period patient was treated with VINCRISTINE (See Image) (View Vincristine Review and Vincristine Label ), PREDNISONE (See Image) (View Prednisone Review and Prednisone Label ), PEG ASPARIGINASE (See Image) (View Peg-aspariginase Review and Peg-aspariginase Label ), PEG ASPARIGINASE (See Image) (View Peg-aspariginase Review and Peg-aspariginase Label ). Patient was hospitalized.

4846199-4 | Catheter Sepsis, Echocardiogram Abnormal
on Dec 02, 2005 Male patient from UNITED STATES , weighting 111.3 lb, was diagnosed with acute myeloid leukaemia and was treated with Daunorubicin (View Usage). After Daunorubicin was administered, patient had the following side effects: catheter sepsis, echocardiogram abnormal. Daunorubicin dosage: See Image. During the same period patient was treated with MITOXANTRONE (See Image) (View Mitoxantrone Review and Mitoxantrone Label ). Patient was hospitalized.

4840614-8 | Activated Partial Thromboplastin Time Prolonged, Blood Fibrinogen Decreased, Prothrombin Time Prolonged, Pulmonary Embolism
on Nov 29, 2005 Female patient from UNITED STATES , weighting 153.2 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Daunorubicin (View Usage). Patient experienced the following unwanted or unexpected effects: activated partial thromboplastin time prolonged, blood fibrinogen decreased, prothrombin time prolonged, pulmonary embolism (What is pulmonary embolism?). Daunorubicin dosage: See Image. During the same period patient was treated with VINCRISTINE SULFATE (See Image) (View Vincristine Sulfate Review and Vincristine Sulfate Label ), L ASPARAGINASE (See Image) (View L-asparaginase Review and L-asparaginase Label ), METHOTREXATE (See Image) (View Methotrexate Review and Methotrexate Label ), PREDNISONE (See Image) (View Prednisone Review and Prednisone Label ).

4833741-2 | Clostridium Difficile Toxin Test Positive, Diarrhoea, Pain, Pyrexia
Patient was taking Daunorubicin (View Usage). Patient had the following side effects: clostridium difficile toxin test positive, diarrhoea, pain (What is pain?), pyrexia on Nov 16, 2005 from UNITED STATES Additional patient health information: Male patient , weighting 154.3 lb, was diagnosed with haematopoietic neoplasm and. Daunorubicin dosage: See Image. During the same period patient was treated with CYTARABINE (See Image) (View Cytarabine Review and Cytarabine Label ), ZOSUQUIDAR (See Image) (View Zosuquidar Review and Zosuquidar Label ). Patient was hospitalized.

4815451-0 | Asthenia, Atelectasis, Blood Bilirubin Increased, Chest Pain, Cholelithiasis, Computerised Tomogram Abnormal, Ejection Fraction Decreased, Hepatosplenic Candidiasis, Infection
Adverse event was reported on Oct 27, 2005 by a Male patient taking Daunorubicin (View Usage) (Dosage: See Image) was diagnosed with acute lymphocytic leukaemia and. Location: UNITED STATES , weighting 171.1 lb, After Daunorubicin was administered, patient had the following side effects: asthenia, atelectasis, blood bilirubin increased, chest pain (What is chest pain?), cholelithiasis, computerised tomogram abnormal, ejection fraction decreased, hepatosplenic candidiasis, infection (What is infection?). During the same period patient was treated with VINCRISTINE SULFATE (See Image) (View Vincristine Sulfate Review and Vincristine Sulfate Label ), PREDNISONE (See Image) (View Prednisone Review and Prednisone Label ), L ASPAGINASE (See Image) (View L-aspaginase Review and L-aspaginase Label ), METHOTREXATE (See Image) (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

4808776-6 | Chest Pain, Gastritis, Infection, Loss Of Consciousness, Neutropenia, Pyrexia
on Oct 20, 2005 Male patient from UNITED STATES , weighting 207.5 lb, was diagnosed with precursor b-lymphoblastic lymphoma and was treated with Daunorubicin (View Usage). Patient experienced the following unwanted or unexpected effects: chest pain (What is chest pain?), gastritis, infection (What is infection?), loss of consciousness, neutropenia, pyrexia. Daunorubicin dosage: See Image. During the same period patient was treated with PREDNISONE (See Image) (View Prednisone Review and Prednisone Label ), VINCRISTINE (See Image) (View Vincristine Review and Vincristine Label ), ARA C (See Image) (View Ara-c Review and Ara-c Label ), METHOTREXATE (See Image) (View Methotrexate Review and Methotrexate Label ), CYTOXAN (See Image) (View Cytoxan Review and Cytoxan Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), PERCOCET (View Percocet Review and Percocet Label ).

4805964-X | Cholecystitis, Hyperbilirubinaemia
on Oct 19, 2005 Female patient from UNITED STATES , weighting 188.9 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Daunorubicin (View Usage). Patient had the following side effects: cholecystitis, hyperbilirubinaemia. Daunorubicin dosage: See Image. During the same period patient was treated with VINCRISTINE SULFATE (See Image) (View Vincristine Sulfate Review and Vincristine Sulfate Label ), PREDNISONE (See Image) (View Prednisone Review and Prednisone Label ), L ASPARAGINASE (See ,age) (View L-asparaginase Review and L-asparaginase Label ), METHOTREXATE (See Image) (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

4805962-6 | Atrial Fibrillation, Chest Pain, Electrocardiogram T Wave Abnormal, Haemodynamic Instability, Hypotension, Hypoxia, Infection, Pericardial Effusion, Pericarditis
Patient was taking Daunorubicin (View Usage). After Daunorubicin was administered, patient had the following side effects: atrial fibrillation (What is atrial fibrillation?), chest pain (What is chest pain?), electrocardiogram t wave abnormal, haemodynamic instability, hypotension, hypoxia, infection (What is infection?), pericardial effusion, pericarditis on Oct 19, 2005 from UNITED STATES Additional patient health information: Female patient , weighting 202.2 lb, was diagnosed with acute myeloid leukaemia and. Daunorubicin dosage: See Image. During the same period patient was treated with CYTARABINE (See Image) (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

4805956-0 | Atrial Fibrillation, Chest Pain, Electrocardiogram T Wave Abnormal, Haemodynamic Instability, Hypotension, Hypoxia, Infection, Pericardial Effusion, Pericarditis
Adverse event was reported on Oct 19, 2005 by a Female patient taking Daunorubicin (View Usage) (Dosage: See Image) was diagnosed with acute myeloid leukaemia and. Location: UNITED STATES , weighting 202.2 lb, Patient experienced the following unwanted or unexpected effects: atrial fibrillation (What is atrial fibrillation?), chest pain (What is chest pain?), electrocardiogram t wave abnormal, haemodynamic instability, hypotension, hypoxia, infection (What is infection?), pericardial effusion, pericarditis. During the same period patient was treated with CYTARABINE (See Image) (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

4786216-3 | Cardio-respiratory Arrest, Klebsiella Sepsis, Mass, Neutropenic Sepsis, Tonsillar Disorder
on Oct 03, 2005 Male patient from UNITED STATES , weighting 143.3 lb, was diagnosed with acute myeloid leukaemia and was treated with Daunorubicin (View Usage). Patient had the following side effects: cardio-respiratory arrest, klebsiella sepsis, mass, neutropenic sepsis, tonsillar disorder. Daunorubicin dosage: See Image. During the same period patient was treated with CYTARABINE (See Image) (View Cytarabine Review and Cytarabine Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), ANCEF (View Ancef Review and Ancef Label ), BENADRYL (View Benadryl Review and Benadryl Label ), CEFEPIME (View Cefepime Review and Cefepime Label ), CHLORHEXADINE (View Chlorhexadine Review and Chlorhexadine Label ), DEMEROL (View Demerol Review and Demerol Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized.

4733011-7 | Abdominal Pain, Blood Culture Positive, Bloody Discharge, Caecitis, Coagulopathy, Ecchymosis, Enterococcal Sepsis, Haemodialysis, Hyperglycaemia
on Aug 01, 2005 Male patient from UNITED STATES , 13 years of age, weighting 204.4 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Daunorubicin (View Usage). After Daunorubicin was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), blood culture positive, bloody discharge, caecitis, coagulopathy, ecchymosis, enterococcal sepsis, haemodialysis, hyperglycaemia. Daunorubicin dosage: 50 Mg Q Week Intravenou. During the same period patient was treated with VINCRISTINE (2mg Q Week Intravenou) (View Vincristine Review and Vincristine Label ), CEFEPIME (View Cefepime Review and Cefepime Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ), TOBRAMYCIN (View Tobramycin Review and Tobramycin Label ), ALTERNAGEL (View Alternagel Review and Alternagel Label ), PEPCID (View Pepcid Review and Pepcid Label ), DIFLUCAN (View Diflucan Review and Diflucan Label ). Patient was hospitalized.

4725594-8 | Gastrointestinal Mucositis, Haematochezia, Haematocrit Decreased, Haemoglobin Decreased, Neutrophil Count Decreased, Platelet Count Decreased
Patient was taking Daunorubicin (View Usage). Patient experienced the following unwanted or unexpected effects: gastrointestinal mucositis, haematochezia, haematocrit decreased, haemoglobin decreased, neutrophil count decreased, platelet count decreased on Jul 22, 2005 from UNITED STATES Additional patient health information: Female patient , 16 years of age, was diagnosed with myeloid leukaemia and. Daunorubicin dosage: . During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

4714506-9 | Electrocardiogram Qt Prolonged, Sinus Bradycardia
Adverse event was reported on Jul 07, 2005 by a Male patient taking Daunorubicin (View Usage) (Dosage: ) was diagnosed with acute lymphocytic leukaemia, disturbance in attention and. Location: , 13 years of age, weighting 119.0 lb, Patient had the following side effects: electrocardiogram qt prolonged, sinus bradycardia. During the same period patient was treated with RISPERDAL (View Risperdal Review and Risperdal Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), ZOFRAN (View Zofran Review and Zofran Label ), ENDOXAN (View Endoxan Review and Endoxan Label ), ASPARAGINASE (View Asparaginase Review and Asparaginase Label ), PURINETHOL (View Purinethol Review and Purinethol Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), COTRIMOXAZOL (View Cotrimoxazol Review and Cotrimoxazol Label ).

4686019-4 | Disseminated Intravascular Coagulation, Haemodialysis, Multi-organ Failure, Pulmonary Oedema, Respiratory Distress
on May 19, 2005 Female patient from , child 9 years of age, was diagnosed with agranulocytosis and was treated with Daunorubicin (View Usage). After Daunorubicin was administered, patient had the following side effects: disseminated intravascular coagulation, haemodialysis, multi-organ failure, pulmonary oedema, respiratory distress. Daunorubicin dosage: 60 Mg Iv. During the same period patient was treated with CYTARABINE (230 Mg Iv) (View Cytarabine Review and Cytarabine Label ), METHOTREXATE (12 Mg Once Inj) (View Methotrexate Review and Methotrexate Label ), VANCOMYCIN HYDROCHLORIDE (2 G Inj) (View Vancomycin Hydrochloride Review and Vancomycin Hydrochloride Label ), TOBRAMYCIN (210 Mg Inj) (View Tobramycin Review and Tobramycin Label ), TEICOPLANIN (350 Mg Iv) (View Teicoplanin Review and Teicoplanin Label ), CEFTRIAXZONE SODIUM (2 G Inj) (View Ceftriaxzone Sodium Review and Ceftriaxzone Sodium Label ), TRETINOIN (50 Mg Po) (View Tretinoin Review and Tretinoin Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ).

4650602-2 | Colitis, Diarrhoea, Neutropenia
on Apr 28, 2005 Female patient from , weighting 209.7 lb, was diagnosed with acute myeloid leukaemia and was treated with Daunorubicin (View Usage). Patient experienced the following unwanted or unexpected effects: colitis, diarrhoea, neutropenia. Daunorubicin dosage: 90 Mg/m2/day, Iv Days 1-3. During the same period patient was treated with CYTARABINE (100 Mg/m2/day, Iv, Days 1-7) (View Cytarabine Review and Cytarabine Label ), GM CSF (At 250 Mcg/m2 To Next Vial Size, Anc }/= To 1,000) (View Gm-csf Review and Gm-csf Label ).

4646223-8 | Abdominal Pain, Febrile Neutropenia, Orthostatic Hypotension
Patient was taking Daunorubicin (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), febrile neutropenia, orthostatic hypotension on Apr 22, 2005 from Additional patient health information: Male patient , weighting 179.2 lb, was diagnosed with myelodysplastic syndrome and. Daunorubicin dosage: 45 Mg/m2/day, Days 1-3, Iv. During the same period patient was treated with CYTARABINE (100 Mg/m2/day, Days 1-7, Iv) (View Cytarabine Review and Cytarabine Label ), ZOSUQUIDAR TRIHYDROCHLORIDE (550 Mg/days, Days 1-3, Iv) (View Zosuquidar Trihydrochloride Review and Zosuquidar Trihydrochloride Label ), NEUPOGEN (Until Anc }/=500 Cells For 3 Consevcutives Days.) (View Neupogen Review and Neupogen Label ).

4591148-X | Haematocrit Decreased, Haemoglobin Decreased, Haemorrhoidal Haemorrhage, Pancytopenia, Rectal Haemorrhage
Adverse event was reported on Feb 22, 2005 by a Male patient taking Daunorubicin (View Usage) (Dosage: 60 Mg/m2 /day By Ivp On Day 1-3) . Location: , weighting 158.3 lb, After Daunorubicin was administered, patient had the following side effects: haematocrit decreased, haemoglobin decreased, haemorrhoidal haemorrhage, pancytopenia, rectal haemorrhage. During the same period patient was treated with CYTARABINE (100 Mg/m2 /day By Civ On Days 1-7) (View Cytarabine Review and Cytarabine Label ).

4590857-6 | Clostridium Colitis, Intestinal Obstruction, Mass, Soft Tissue Disorder
on Feb 22, 2005 Male patient from , weighting 192.2 lb, was treated with Daunorubicin (View Usage). Patient experienced the following unwanted or unexpected effects: clostridium colitis, intestinal obstruction, mass, soft tissue disorder. Daunorubicin dosage: 60 Mg /m2/ Day By Ivp On Days 1-3. During the same period patient was treated with CYTARABINE (100 Mg/m2 /day By Civ On Days 1-7) (View Cytarabine Review and Cytarabine Label ).

4585584-5 | Hypovolaemic Shock, Pancreatic Pseudocyst, Pancreatitis Haemorrhagic, Systemic Inflammatory Response Syndrome
on Jan 13, 2005 Female patient from , child 5 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Daunorubicin (View Usage). Patient had the following side effects: hypovolaemic shock, pancreatic pseudocyst, pancreatitis haemorrhagic, systemic inflammatory response syndrome. Daunorubicin dosage: . During the same period patient was treated with ELSPAR (View Elspar Review and Elspar Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

4568114-3 | Chronic Myeloid Leukaemia, Pneumonia, Skin Disorder
Patient was taking Daunorubicin (View Usage). After Daunorubicin was administered, patient had the following side effects: chronic myeloid leukaemia, pneumonia (What is pneumonia?), skin disorder on Jul 06, 2004 from Additional patient health information: Male patient , 59 years of age, was diagnosed with acute promyelocytic leukaemia and. Daunorubicin dosage: . During the same period patient was treated with MITOXANTRONE (View Mitoxantrone Review and Mitoxantrone Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), VINDESINE (View Vindesine Review and Vindesine Label ).

4563051-2 | Chronic Myeloid Leukaemia, Leukaemia Recurrent, Pneumonia
Adverse event was reported on Jul 06, 2004 by a Male patient taking Daunorubicin (View Usage) (Dosage: ) was diagnosed with acute promyelocytic leukaemia and. Location: , 59 years of age, Patient experienced the following unwanted or unexpected effects: chronic myeloid leukaemia, leukaemia recurrent, pneumonia (What is pneumonia?). During the same period patient was treated with MITOXANTRONE (View Mitoxantrone Review and Mitoxantrone Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), VINDESINE (View Vindesine Review and Vindesine Label ).